• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CAI International, Inc. Stockholders Approve Merger Agreement for Acquisition by Mitsubishi HC Capital Inc.

    9/2/21 4:05:00 PM ET
    $CAI
    Medical Specialities
    Health Care
    Get the next $CAI alert in real time by email

    CAI International, Inc. (NYSE:CAI) ("CAI" or the "Company"), one of the world's leading transportation finance companies, announced today that the Company's common stockholders, at a special meeting of the Company's common stockholders held earlier today (the "Special Meeting"), voted to adopt the previously announced merger agreement for the acquisition of the Company by Mitsubishi HC Capital Inc. ("MHC"). Under the terms of the merger agreement, the Company's common stockholders will be entitled to receive $56.00 per share in cash at the closing of the acquisition. The transaction is expected to close in the late third quarter or early fourth quarter of 2021.

    Upon completion of the acquisition, CAI will become privately held as a wholly-owned subsidiary of MHC.

    According to the final voting results, approximately 75% of the Company's outstanding shares of common stock were cast, as of the close of business on August 2, 2021, the record date for the Special Meeting, with approximately 99% of the votes cast voting in favor of the merger agreement.

    The consummation of the merger remains subject to the satisfaction or waiver of certain other closing conditions set forth in the merger agreement (including completion of the Migration (as defined in the merger agreement)) and discussed in detail in the definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC") by the Company on August 4, 2021 (as supplemented, the "Definitive Proxy Statement").

    About CAI International, Inc.

    CAI is one of the world's leading transportation finance companies. As of June 30, 2021, CAI operated a worldwide fleet of approximately 1.9 million CEUs of containers. CAI operates through 13 offices located in 12 countries including the United States.

    Forward-Looking Statements

    This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. All statements included in this communication, other than statements of historical fact, are forward-looking statements. Statements about the expected timing, completion and effects of the proposed merger and related transactions and all other statements in this communication, other than historical facts, constitute forward-looking statements. When used in this communication, the words "expect," "believe," "anticipate," "goal," "plan," "intend," "estimate," "may," "will" or similar words are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date hereof and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. The Company may not be able to complete the proposed merger on the terms described herein or other acceptable terms or at all because of a number of factors, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement, (2) the failure to satisfy the closing conditions in the merger agreement (including the Migration (as defined in the Definitive Proxy Statement)), (3) the potential for regulatory authorities to require divestitures, behavioral remedies or other concessions in order to obtain their approval of the proposed merger, (4) risks related to disruption of management's attention from the Company's ongoing business operations due to the proposed merger, (5) the effect of the announcement of the proposed merger on the ability of the Company to retain and hire key personnel and maintain relationships with its customers, suppliers, operating results and business generally, (6) the proposed merger may involve unexpected costs, liabilities or delays, (7) the Company's business may suffer as a result of the uncertainty surrounding the proposed merger, including the timing of the consummation of the proposed merger, (8) the outcome of any legal proceeding relating to the proposed merger, (9) the Company may be adversely affected by other economic, business and/or competitive factors, including, but not limited to, those related to COVID-19, and (10) other risks to consummation of the proposed merger, including the risk that the proposed merger will not be consummated within the expected time period or at all, which may adversely affect the Company's business and the price of the common stock.

    Actual results may differ materially from those indicated by such forward-looking statements. In addition, the forward-looking statements represent the Company's views as of the date on which such statements were made. The Company anticipates that subsequent events and developments may cause its views to change. However, although the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. Additional factors that may affect the business or financial results of the Company are described in the risk factors included in the Company's filings with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 1, 2021, as updated by the Company's subsequent filings with the SEC. The Company expressly disclaims a duty to provide updates to forward-looking statements, whether as a result of new information, future events or other occurrences, except as required by applicable law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005838/en/

    Get the next $CAI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CAI

    DatePrice TargetRatingAnalyst
    4/13/2026$28.00Buy
    Jefferies
    4/10/2026$21.00Neutral
    Piper Sandler
    4/1/2026$27.00Buy
    Goldman
    2/17/2026$26.00Outperform
    Robert W. Baird
    12/2/2025$28.00Hold
    Canaccord Genuity
    7/14/2025$31.00Buy
    BofA Securities
    7/14/2025$31.00Overweight
    Analyst
    7/14/2025$32.00Buy
    Guggenheim
    More analyst ratings

    $CAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Caris Life Sciences with a new price target

    Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00

    4/13/26 8:51:07 AM ET
    $CAI
    Medical Specialities
    Health Care

    Piper Sandler initiated coverage on Caris Life Sciences with a new price target

    Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00

    4/10/26 8:31:01 AM ET
    $CAI
    Medical Specialities
    Health Care

    Goldman initiated coverage on Caris Life Sciences with a new price target

    Goldman initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $27.00

    4/1/26 8:30:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

    IRVING, Texas, April 17, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the UCSF Helen Diller Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance® (POA). The Caris POA is a global network of leading cancer centers and research groups that collaborate to advance precision oncology and biomarker-driven research. "Welcoming UCSF Helen Diller Family Comprehensive Cancer Center to the Caris Precision Oncology Alliance underscores

    4/17/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

    Comprehensive molecular profiling paired with biomarker-driven trial matching provides cancer patients with a complete pathway from diagnosis to treatment across more than 600 locations nationwideIRVING, Texas, April 15, 2026 /PRNewswire/ -- Caris Life Sciences®, Inc. (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today highlighted the growing urgency of closing the geographic gap in cancer clinical trial access and the role its Right-In-Time (RIT) clinical trial solution plays in bringing biomarker-driven trials to community oncology practices nationwide.

    4/15/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CAI
    SEC Filings

    View All

    $CAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Denton John Russel bought $100,793 worth of shares (4,184 units at $24.09) (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:12:42 AM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley bought $9,540 worth of shares (400 units at $23.85), increasing direct ownership by 0.09% to 460,777 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    11/10/25 8:11:33 AM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel returned $4,431,078 worth of shares to the company (238,230 units at $18.60), was granted 99,321 shares and bought $157,500 worth of shares (7,500 units at $21.00), decreasing direct ownership by 52% to 123,591 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    6/23/25 6:34:51 PM ET
    $CAI
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Caris Life Sciences Inc.

    SCHEDULE 13G/A - Caris Life Sciences, Inc. (0002019410) (Subject)

    4/7/26 1:21:16 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    4/2/26 4:28:46 PM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Caris Life Sciences, Inc. (0002019410) (Filer)

    2/26/26 4:11:03 PM ET
    $CAI
    Medical Specialities
    Health Care

    President Spetzler David Baxley was granted 83,162 shares, increasing direct ownership by 18% to 543,939 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 5:59:58 PM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form 4 filed by Caris Life Sciences Inc.

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:01:21 PM ET
    $CAI
    Medical Specialities
    Health Care

    Officer Denton John Russel was granted 63,971 shares, increasing direct ownership by 52% to 187,562 units (SEC Form 4)

    4 - Caris Life Sciences, Inc. (0002019410) (Issuer)

    3/10/26 6:00:25 PM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Financials

    Live finance-specific insights

    View All

    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

    IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion

    4/20/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

    IRVING, Texas, Feb. 9, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Thursday, February 26, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/49czfgs4 A replay of th

    2/9/26 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

    IRVING, Texas, Oct. 23, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report third quarter 2025 financial results on Wednesday, November 5, 2025. Caris Life Sciences will host a conference call and live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results. Conference Call Details: Date: Wednesday, November 5, 2025Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/uwjxydsa A replay of the webcast will

    10/23/25 8:30:00 AM ET
    $CAI
    Medical Specialities
    Health Care

    $CAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by CAI International, Inc. (Amendment)

    SC 13G/A - CAI International, Inc. (0001388430) (Subject)

    12/10/21 10:00:15 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    11/12/21 9:17:56 AM ET
    $CAI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by CAI International, Inc.

    SC 13G - CAI International, Inc. (0001388430) (Subject)

    10/7/21 4:07:36 PM ET
    $CAI
    Medical Specialities
    Health Care